Loading clinical trials...
Loading clinical trials...
Lacticaseibacillus Rhamnosus CA15 (DSM 33960) Strain as a New Driver in Restoring the Normal Vaginal Microbiota: a Randomized, Double-blind, Placebo-controlled Clinical Trial
Conditions
Interventions
Lacticaseibacillus rhamnosus CA15 (DSM 33960) probiotic strain
placebo
Locations
1
Italy
University of Catania
Catania, Italy, Italy
Start Date
April 10, 2023
Primary Completion Date
June 29, 2024
Completion Date
May 6, 2025
Last Updated
July 28, 2025
NCT05488340
NCT07394777
NCT01829204
NCT07233473
NCT07186465
NCT04846803
Lead Sponsor
Agnese Maria Chiara Rapisarda
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions